An EUA for tocilizumab (Actemra) for COVID-19.

Med Lett Drugs Ther ; 63(1629): 113-114, 2021 Jul 26.

Article in English | MEDLINE | ID: covidwho-1426728

Subject(s)

Antibodies, Monoclonal, Humanized/administration & dosage; COVID-19 Drug Treatment; Drug Approval/legislation & jurisprudence; Receptors, Interleukin-6/antagonists & inhibitors; United States Food and Drug Administration/legislation & jurisprudence; Antibodies, Monoclonal, Humanized/pharmacokinetics; COVID-19/epidemiology; COVID-19/immunology; COVID-19/prevention & control; Clinical Trials as Topic/methods; Humans; Receptors, Interleukin-6/immunology; United States/epidemiology

Keywords

Actemra; COVID-19; Corticosteroids; Olumiant; adverse effects; baricitinib; dexamethasone; dosage; drug interactions; efficacy; remdesivir; safety; tocilizumab

Search on Google

XML

PubMed Links

Collection: International databases Database: MEDLINE Main subject: United States Food and Drug Administration / Drug Approval / Receptors, Interleukin-6 / Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Med Lett Drugs Ther Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML

PubMed Links